-

Pope Leo XIV embraces paediatric patients at CNAO in Pavia
PAVIA, Italy, June 20, 2026 /PRNewswire/ — The National Center for Oncological Hadrontherapy (CNAO) served as the first stop today during Pope Leo XIV’s pastoral visit to the city of Pavia. His choice to begin his journey at this center reflects a profound commitment to fostering meaningful dialogue between advanced scientific progress and the alleviation…
-

Millionaires on the Move: Winners, Losers, and the Global Competition for Wealth in 2026
LONDON, June 16, 2026 /PRNewswire/ — Singapore, Italy, Switzerland, Greece, Hong Kong, and New Zealand are emerging as some of the most attractive destinations for internationally mobile wealth in 2026 , while the United Kingdom, Germany, France, Norway, and South Korea are facing growing competitiveness pressures as tax reforms, fiscal uncertainty, and policy shifts prompt…
-

IMG Shares 2026 Summer Travel Insights: Higher Spending and Longer Trips
IMG reviewed the travel itineraries of more than 30,000 of its members with upcoming travel plans between June 1st and August 31st of 2026 to determine notable travel trends this summer. INDIANAPOLIS, May 27, 2026 /PRNewswire/ — IMG (International Medical Group) has completed its annual review of summer travel data based on customer travel plans…
-
Chiesi Global Rare Diseases Announces European Commission Approval of LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolaemia (HoFH)
European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels June 05, 2026 02:00 ET | Source: Chiesi Global Rare Diseases PARMA, Italy, June 05, 2026 (GLOBE NEWSWIRE) — Chiesi Global Rare Diseases, a…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.






